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Abstract
Mesenchymal stem cell (MSC) encapsulation technique has long been emerged in tissue engineering as it plays an
important role in implantation of stem cells to regenerate a damaged tissue. MSC encapsulation provides a mimic
of a three-dimensional (3D) in vivo environment to maintain cell viability and to induce the stem cell differentiation
which regulates MSC fate into multi-lineages. Moreover, the 3D matrix surrounding MSCs protects them from the
human innate immune system and allows the diffusion of biomolecules such as oxygen, cytokines, and growth
factors. Therefore, many technologies are being developed to create MSC encapsulation platforms with diverse
materials, shapes, and sizes. The conditions of the platform are determined by the targeted tissue and translation
method. This review introduces several details of MSC encapsulation technologies such as micromolding, electrostatic
droplet extrusion, microfluidics, and bioprinting and their application for tissue regeneration. Lastly, some of
the challenges and future direction of MSC encapsulation technologies as a cell therapy-based tissue regeneration
method will be discussed.
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Background
To treat tissue and organ injuries, cell-based therapy
through the transplantation of stem cells into the dam-
aged site to generate new tissue has been the novel ap-
proach for tissue regeneration. Among the various types
of stem cells, mesenchymal stem cells (MSCs) are com-
monly used for cell therapy because of many advantages,
such as their capacity for self-renewal and differentiation
into multi-lineages without ethical issue. Moreover, they
have a low risk of teratoma development and low im-
munogenicity [1, 2]. MSCs can be derived from many
types of tissues, for example, the bone marrow, adipose
tissue, umbilical cord blood, placenta, lung, liver, and
skin [3, 4]. Thus, MSCs have been observed to differenti-
ate into many types of tissue including bone, cartilage,
muscle, fat, tendon, ligament, and other connective tis-
sues [5]. Moreover, MSCs secrete various cytokines and
growth factors such as interleukin-2 (IL-2), interleukin-8
(IL-8), monocyte chemotactic protein-1 (MCP-1),
stromal-derived factor-1 (SDF-1), vascular endothelial
growth factor (VEGF), and transforming growth
factor-beta (TGF-β) which regulate the immune system
as well as many intercellular signaling pathways [6, 7].
These secreted bioactive molecules stimulate organoty-
pic cells, enhancing their activities, and reduce fibrosis
and apoptosis [8]. Therefore, MSCs are not only capable
of differentiation, but also of affecting various reactions
and signaling pathways in the human body.
To deliver MSCs and maintain their advantages (i.e.,
their capacity for viability and differentiation) in damaged
tissues, it is essential to mimic the in vivo microenviron-
ment through three-dimensional (3D) construction and as
such retain the cell’s various effects under the 3D environ-
ment, such as their phenotype, adhesion, metabolism, and
response signal to soluble factors [9]. In fact, cells show
different physiological and morphological results in
two-dimensional (2D) and 3D environments [10]. In par-
ticular, MSCs have better osteogenic [11], adipogenic [12],
and hepatic [13, 14] differentiation behavior in the 3D
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environment. Moreover, MSCs show improved differenti-
ation when they are co-cultured with other types of cells
such as human umbilical vein endothelial cells (HUVECs)
[15], osteoblasts [16], and hematopoietic stem/progenitor
cells (HSPCs) [17] compared with those cultured alone in
the 3D environment. This is because MSCs interact with
other cells differently in the 3D environment compare
with the 2D monolayer environment, which enhances the
co-culture effect and results in increased cell expansion
and tissue regeneration.
The encapsulation of MSCs, by entrapping the viable
cells in a 3D semi-permeable hydrogel matrix, is one of
the simple methods to introduce a 3D environment. The
cell encapsulation is accomplished through the solidifi-
cation of a cell-suspended liquid material [18]. The 3D
cell-encapsulating matrix should safely deliver the MSCs
and maintain their viability and function in vitro and in
vivo to ultimately have therapeutic potential. Success-
fully encapsulated MSCs can then differentiate into the
targeted lineages, for example, tendon [19], interverte-
bral disk [20], bone [21], and articular cartilage [22]. Ac-
cordingly, the encapsulation of MSCs into a 3D matrix
is a very efficient and effective method in tissue regener-
ation, and many 3D encapsulation technologies have
been developed as powerful tools for regenerative medi-
cine. A variety of cell encapsulation technologies can
produce 3D matrices of various shapes and sizes, which
affect the viability and differentiation of MSCs. For ef-
fective tissue regeneration, the shape and size of the 3D
matrix must be determined selectively, depending on the
property of the target tissue and the materials used
(Table 1). Therefore, it is crucial to understand the prin-
ciples and processes of the various MSC encapsulation
technologies in order to select the most efficient and ef-
fective one for the intended purpose.
In this review, we discuss the various MSC encapsula-
tion technologies, from the old methods to the recently
developed ones. We also describe several applicable tis-
sue regeneration strategies with the introduced encapsu-
lation technologies. Finally, the challenges of MSC
encapsulation and its future direction for tissue regener-
ation will be presented.
MSC encapsulation technology
To overcome the 2D environment, the first attempt of a
3D network for cells was the hanging drop tissue culture
system developed by Ross Harrison in 1906 [23]. How-
ever, the first introduction of cell encapsulation occurred
in the 1960s, when Chang proposed the development of
semipermeable microcapsules using nylon membranes
by an emulsification method in 1964 [24]. In other stud-
ies, using emulsification methods, collagen-agarose [25]
and peptides [26] were introduced as the 3D microenvir-
onment for cells. After the early successful strategy by
Chang, cell encapsulation within beads and matrices was
studied extensively. One of the most common methods
for cell encapsulation is entrapment of cells within
hydrogel beads which is a very convenient technique
that is still being used at present because of its simplicity
and stable formation. It was easily achieved by dropping
the alginate hydrogel from a syringe into a calcium
chloride solution [27]. Aside from the alginate material,
this method was also applied to fabricate various cell en-
capsulation membranes through ionic crosslink forma-
tion [28–30]. In addition, processes such as coaxial air
jet application and the liquid jet method were developed
for cell-entrapped droplet formation. Other developed
methods including the macromolecular collagen type I
matrix [31], hollow fibers produced by injection and
co-extrusion [32], and photopolymerization by UV to re-
duce cell death without organic solvent were developed.
Among these preliminary methods, some technologies
are still being used in the same or better way to this day.
The widespread and newly developed cell encapsulation
technologies, including micromolding, electrostatic
droplet extrusion, microfluidics, and bioprinting have
been studied since 1958. Recently, microfluidics and bio-
printing are widely applied for cell encapsulation. Also,
4D printing technology in which biomaterials or cells
are responsive to external stimuli has been developed
[33]. With the increasing interest in MSCs, many re-
search groups have started to encapsulate MSCs for
cell-based therapy (Fig. 1). Therefore, in this section, we
will review the principles behind these technologies with
a focus on MSC encapsulation.
Micromolding method
The micromolding method was used to fabricate the
cell-laden constructs on a massive scale using specialized
lithography equipment. For cell encapsulation, micro-
molding is a powerful tool that regulates the cellular
microenvironment while encapsulating MSCs using spe-
cialized lithography equipment (Fig. 2a). Micromolding
is the proper technology to manufacture a uniform cap-
sule with excellent reproducibility, which is the reason
for its extensive use. There are several types of micro-
molding methods, including replica, capillary, imprint-
ing, and microtransfer molding. Among these methods,
replica molding and capillary molding are easy to manu-
facture and have excellent repeatability at low cost, so
they are currently widely used.
Replica molding is a process in which structures of
various shapes and sizes are fabricated by diverse types
of molds, using the gelation of a precursor polymer [34].
Polydimethylsiloxane (PDMS) membranes are the most
commonly used templates for the gel structures. The
polymer solution is poured onto a master made of a sili-
con substrate and microstructure, and the cured PDMS
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Table 1 Summary of encapsulation technologies with diverse materials and MSC types for different target tissues
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Fig. 1 Technical history and principal description of the technologies developed to achieve cell encapsulation, by year. a Micromolding was used
in a variety of fields, but not for cell encapsulation until the early 1980s. Lithography based on micromolding was founded by Broers et al. [92]
whereas techniques using replica [93] and capillary molding [94] were developed in 1996, and MSC encapsulation began in 2002. b Nawab and
Mason suggested liquid droplets under electrostatic fields, which formed the principle of electrostatic droplet extrusion in 1958 [95]. For cell
encapsulation using this technology, Goosen et al. proposed cell immobilization within a semipermeable membrane [96]. Moreover, Bugarski et
al. proved the mechanism of polymer droplet formation with electrostatic droplet extrusion in 1994 [42]. Finally, MSC encapsulation was
conducted in the late 2000s [97, 98]. c Schmidt et al. introduced a microfluidic device in 1990 [99], and the cell encapsulation was studied by
Sugiura in 2005 [100]. Zhang et al. generated microgel particles with a capsular structure [101]. Microfluidic emulsification, achieved by Edd et al.,
offered enhanced controls over a number of encapsulated cells [102]. In 2010, MSC encapsulation was beginning to be studied. d The 3D printer
was invented by Charles W. Hull in 1983 [103]. The inkjet 3D printing-based hard tissue scaffold was developed by Gima et al. in the early 1990s
[104], which was an earlier step for application into soft tissue engineering [105]. Cell-laden and MSC-encapsulated 3D bioprinting was attempted
form the 2000s onward after the development of the cell-free printed scaffold [74]. Finally, 4D bioprinting was developed as an advanced bioprinting
technique for next-generation technology in the biomedical fields [106]
Fig. 2 MSC encapsulation technologies. The techniques for encapsulation of MSCs to maintain their viability, proliferation, and differentiation
function to deliver the cells into damaged tissues in a 3D microenvironment are achieved through a micromolding (reproduced with permission
from Reference [38]. Copyright 2013 John Wiley and Sons), b electrostatic droplet extrusion, c microfluidics (reproduced with permission from
Reference [87]. Copyright 2013 Springer Nature and reproduced with permission from Reference [65]. Copyright 2017 IOP Publishing), and d
bioprinting (reproduced with permission from Reference [107]. Copyright 2018 IOP Publishing) technologies. These technologies create various
types of cell encapsulation platforms (e.g., microbeads, bulk matrices, and fiber) and specific shapes
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is then peeled off from the master [35]. To encapsulate
cells with molding, the membrane is immersed in a
cell-suspended polymer solution and then removed after
solidification of the solution. Trkov et al. studied the
vasculogenic potential of MSCs through replica molding
microfabrication [36]. Vorwald et al. claimed that proper
biomaterials should be considered as the molding re-
source for MSC transplantations; for example, the algin-
ate hydrogel effectively encapsulates MSCs as spheroids
[37]. Hamilton et al. designed and implemented a hydro-
gel replica molding, which successfully cultivated two or
more cell types in a highly customized environment that
represented the 3D tissue physiology [38]. They have de-
veloped a 3D hydrogel co-culture system by separating
and isolating different cell populations using
enzyme-sensitive glues. This platform enabled co-culture
effects and cultivation to test the persistence of para-
crine signals and provided great potential for the future
study of various basic cell signals.
Micromolding in a capillary is a convenient technique
for producing a patterned microstructure of an organic
polymer on the surface of a solid substrate. This tech-
nology is achieved by flowing a polymer solution (e.g.,
PDMS fluids) to a prepared capillary patterned mold,
whereupon the PDMS adheres tightly to a flat substrate
and hardened to create a capillary channel. Then,
cell-containing polymer solution is placed at the ends of
channels to create cell encapsulating microtube and
filled automatically into microchannel by capillary force.
The resultant PDMS microchannel creates a partial vac-
uum inside the cavity and plays a role in attracting the
polymer solution [39–41].
Electrostatic droplet extrusion
As an advanced facile technology relative to the simple
syringe extrusion method, the electrostatic droplet ex-
trusion method has been widely studied for MSC micro-
encapsulation (Fig. 2b). Compared with other extrusion
techniques such as air jet extrusion and vibrational en-
capsulation, electrostatic droplet extrusion provides
manufactures with smaller beads with a diameter of less
than 50 μm [42]. Moreover, the advantage of this tech-
nology is that it can be performed under less stressful
conditions without the use of organic solvents that re-
duce cell viability [43]. Even though a high electronic
field is loaded for the process, the electrical potential
does not affect cell viability because the main principle
of electrostatic droplet extrusion is the disruption of a li-
quid jet by electrostatic forces. In this process, liquid is
extruded through a needle connected to the high-voltage
generator. Upon application of a potential to the needle,
the liquid surface is transformed into a Taylor cone-like
droplet, and the liquid cone expands to create a thin
strand. At the end of the electrostatic droplet extrusion
steps, small polymer droplets are formed by detaching
from the aperture of the needle [44]. Furthermore, sev-
eral factors can affect the size of the droplets, such as
the electrostatic potential, the distance between the col-
lecting device and syringe pump, the diameter of the
needles, the flow rate, the type of polymer solution used,
and the concentrations and viscosity of the solution [45].
As already mentioned above, the biopolymer alginate
has been commonly used for cell encapsulation by elec-
trostatic droplet extrusion because of its fast gelation
process based on the ionic crosslinking mechanism. To be
more specific, alginate is a biodegradable and biocompat-
ible copolymer containing β-D-mannuronic acid (M) and
α-L-guluronic acid (G). It has been reported that the G
blocks contribute mainly to the gelation of alginate be-
cause when divalent cations (e.g., Ca2+) are introduced to
an alginate solution, the G blocks in the alginate backbone
form an ionic inter-chain bridge with the cations [46].
Moreover, the alginate hydrogel has a higher mechanical
property than that of other biopolymers and as such is a
suitable material for tissue regeneration. In addition,
alginate-agarose [47], collagen-terpolymer [48], and
arginyl-glycyl-aspartic acid (RGD)-modified alginate mi-
crocapsules [49] have been used to encapsulate cells with
the electrostatic droplet extrusion technique.
Using this technology, Yao et al. produced alginate
microspheres for rat adipose-derived stem cells
(rADSCs) [50]. The rADSC-laden microspheres were
formed by dropping the cell-suspended alginate solu-
tion into a calcium chloride solution. The authors
considered four parameters such as voltage, electrode
distance, push speed, and an inner diameter of the
needle for the encapsulation and transplantation.
They found that the critical factor affecting the mi-
croencapsulation was the electrode distance, that is
the distance between the needle point and the copper
sheet. Furthermore, it was shown that increasing the
flow rate enhanced the production efficiency. In an-
other study group, Moyer et al. developed human-
ADSC (hADSC)-laden microbeads for efficient deliv-
ery into the body by percutaneous injection [51].
They encapsulated hADSCs in alginate microbeads
using an electrostatic droplet generator and confirmed
that smaller beads could be manufactured by increas-
ing the electrical potential to 7 kV and decreasing the
flow rate to < 5 mL/h. They proved that at 3 months
after percutaneous injection of the encapsulated
hADSCs, stable protection of the cells during injec-
tion and in the body had been achieved.
Microfluidic-based cell encapsulation
Microfluidics is a technology based on the manipulation
of a fluid in a microscopic environment, such as a
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microchannel [52]. It involves a variety of microfabrica-
tion processes and presents a promising approach to-
ward the rapid and high-throughput containment of
cells in microgels [53, 54]. The advantages of this tech-
nology are that it enables precise environmental control,
uniform size control with low shear stress, and device
structure control according to various encapsulation
conditions [55]. These microfluidic systems for cell en-
capsulation can be categorized into two major types:
droplets and microfibers (Fig. 2c).
Microfluidic encapsulation in droplets
The microfluidic flow-focusing device is applied to cell
encapsulation with various junction types. To control
the generation of droplets, T-junction and flow-focusing
methods can be applied according to the channel geom-
etry [56]. T-junction is coaxial capillary, and micro-noz-
zle cross-flow system and the size of the orifice of the
T-junction greatly affect the size of the droplets formed.
In the T-junction method, the main channel of the con-
tinuous phase and the inlet channel of the dispersed
phase intersect perpendicularly with each other. The two
phases form a contact at the junction with continuously
flowing fluid in the main channel, and the tip of the dis-
persed phase enters the main channel. The size of the
droplet is changed by controlling the flow rate or chan-
nel width, or by varying the relative viscosity [56–58]. In
the flow-focusing method, the dispersion and continuous
phases are allowed to pass through a narrow region of
the microfluidic device. To better control and stabilize
the droplets, symmetric shearing is used to place the
continuous phase on the dispersed phase. The size of
droplets can be reduced by increasing the speed of the
fluid in the continuous phase [54, 58, 59]. In hydrogel
solutions, cells are generally encapsulated by gelation of
the cell suspension to form a coagulated matrix. The gel-
ation depends on the encapsulating material (e.g., gel-
atin, agarose, alginate, and chitosan) and the cell-laden
hydrogel droplets horizontally distributed to the dis-
persed phase.
Li et al. demonstrated that human bone marrow-de-
rived MSCs (hBMSCs) encapsulated in protein-based
microgels can be a therapeutic candidate for the long-
term maintenance of articular cartilage regeneration
under biocompatible microfluidic processing [60]. Zhao
et al. reported a process that utilized this technology to
facilitate bone regeneration with minimum invasion
[61]. To generate injectable osteogenic tissue constructs,
growth factors and rat BMSCs (rBMSCs) were entrapped
in photocrosslinkable methacrylated gelatin (GelMA)
microspheres. As a result, rBMSCs encapsulated in
GelMA microspheres showed enhanced osteogenesis in
vitro and in vivo.
Microfluidic encapsulation in microfibers
Microfluidic encapsulation in microfibers is defined as
the formation of fibers within a microchannel using the
coaxial flow of the initiating polymer and crosslinker
[62]. Microfluidic fibers can be formed with various
polymers, including gelatin-hydroxyphenylpropionic
acid, alginate, chitosan, gelatin, and poly (lactic-co-glyco-
lic acid) (PLGA). Microfluidic spinning is the proper
technology for cell encapsulation because the fibers can
be continuously produced and cover the cells without
the need for a high voltage or temperature [63]. In
microfluidics, PDMS-based and glass-based microfluidic
chips are mainly used. These types of devices are easily
extruded using similar materials and methods [63, 64].
Liu et al. reported mouse BMSC encapsulated alginate
microfibers using microfluidic technology for vascular
grafts [65]. The generated microfibers were controlled
by the different flow rates and the diameters of a capil-
lary glass tube.
Bioprinting
Bioprinting is an emerging technology for tissue regener-
ation because of its advantages, such as precise control
of the cell density, high-resolution cell deposition, con-
trollable scale, and cost-efficiency. The ultimate goal of
bioprinting is the production of a living organ on a lar-
ger scale for transplantation which is required for many
patients. Furthermore, the printed tissue becomes a pos-
sible tool for studying cell-cell and cell-matrix interac-
tions in microenvironments by mimicking the 3D
extracellular matrix (ECM). The basic concept of this
technology is the layered deposition of cell-laden build-
ing blocks or cell aggregates using several types of rapid
prototyping. There are three primary technologies,
namely, inkjet bioprinting, laser-assisted bioprinting, and
extrusion bioprinting that each with different processes
and benefits (Fig. 2d).
Inkjet bioprinting
Inkjet bioprinting was the first technology of bioprinting
and has a similar concept as conventional inkjet printing
because it uses a cell-bearing pre-polymer solution
(called a bioink solution) for ink cartridge dispensing
[66]. The bioink is squeezed to produce bioink droplets
through stimulation of the printer heads by a thermal
piezoelectric activator [67]. Despite its low cost and
high-throughput production of the parallel cell arrays, it
is limited as a proper technology for tissue regeneration
because it can only generate 2D tissue structure. More-
over, the disadvantages of nozzle clogging when used
with high cell densities, non-uniform droplet size, lack
of structural integrity between droplets, and the possi-
bility of cell exposure to high heating temperature or
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mechanical stress are substantial challenges of this
technology [68].
Although inkjet bioprinting fabricates a 2D structure,
the attempt to generate 3D tissue constructs through a
layer-by-layer method has been widely studied by many
research groups. Gao et al. developed a highly mechan-
ical bone and cartilage using inkjet printing with hMSCs
[69]. They generated a bioprinted PEG-GelMA compos-
ite scaffold layer by layer to introduce a 3D structure for
embedding hMSCs. They confirmed the osteogenesis
and chondrogenesis of the hMSCs for 21 days, with a
high compressive modulus ranging from 1 to 2MPa.
Another research group studied the differentiation abil-
ity of hMSCs in hydrogel blends of type 1 collagen- and
chitosan-agarose that were printed by inkjet bioprinting
[70]. The single drops of hydrogel were dispensed on
top of one another to form a solid column. The hMSCs
showed differentiation tendency toward osteogenic and
adipogenic lineages, confirming that an anisotropic soft
collagen-enriched 3D matrix was suitable for adipogenic
differentiation, whereas an agarose-enriched matrix in-
duced osteogenic differentiation. Therefore, these results
showed that a 3D matrix printed by inkjet bioprinting
was suitable for guiding MSC differentiation fates, and
different types of tissue can be realized through control
of the matrix stiffness.
Extrusion bioprinting
The most common type of 3D bioprinting is extrusion
bioprinting, which was developed from the inkjet bio-
printing technology. It involves extrusion printers, such
as pneumatic and mechanical (piston or screw) dispens-
ing systems, to extrude bioink droplets sequentially by
forming cylindrical lines under a steady force. The major
advantage of extrusion bioprinting is the ability to dis-
pense bioinks with high cell density, which is essential
for forming 3D tissue-derived organs [71]. Furthermore,
since a wide range of viscous materials can be used, the
selection of a variety of materials to encapsulate the cells
is possible. Extrusion bioprinting is also able to produce
multicellular spheroids for forming self-assembled tissue
and organ constructs [72].
Using a customized microextrusion bioprinter, Du et
al. fabricated a 3D bioprinted structure of rBMSC-laden
GelMA scaffolds in the micrometer scale with a
collagen-binding domain [73]. They confirmed the high
cell viability (> 90%) and osteogenic differentiation of
BMSCs for 14 days in the osteogenic medium by evaluat-
ing the gene expression of osteogenic markers, such as
alkaline phosphatase (ALP), bone sialoprotein, osteocal-
cin (OCN), and collagen type I. Another study group
Levato et al. also established bone constructs from
MSC-laden poly(lactic acid) microcarriers encapsulated
in a GelMA-based hydrogel through extrusion
bioprinting [74]. However, there is an obstacle of de-
creasing cell viability because of the extrusion pressure
and the small diameter of the nozzle [75]. Therefore, en-
hancement of the cell viability and maintenance of the
cell function in bioprinting composites are critical chal-
lenges for extrusion bioprinting technology.
Laser-assisted bioprinting
Laser-assisted bioprinting, which is based on
laser-induced transfer, consists mainly of three compo-
nents: a pulsed laser source, a donor layer, and a receiving
substrate [76]. The donor layer is composed of an
energy-absorbing layer (e.g., gold or titanium) on the top
and a layer of mixed bioink solution (e.g., hydrogel and/or
cells) on the bottom. A high-pressure bubble is formed at
the interface of the bioink layer after the energy-absorbing
layer is stimulated by focused laser pulses which evaporate
donor layer part, and then the cell-containing solution is
propelled to the receiving substrate [77]. The advantage of
this technology is the high cell viability achieved as a re-
sult of the low mechanical stress on the cells due to the
non-direct method between the bioink and dispenser. Fur-
thermore, it is possible to deposit highly viscous materials
with the high cell density concentrated bioink [78], and
the bioprinter is able to use various types of bioink.
Gaebel et al. used modified laser-assisted bioprinting
to develop a polyester urethane urea cardiac patch
seeded with hBMSCs and HUVECs in a controlled pat-
tern for cardiac regeneration [79]. They demonstrated
that the co-printing of hBMSCs and HUVECs in the car-
diac patch enhanced both the angiogenesis and the func-
tional neo-vasculature that improves the functionality of
an infarcted heart after transplantation. In another study
group, Gruene et al. generated porcine BMSC-embedded
3D constructs by laser-induced forward transfer to con-
firm the viability and functionality of cells and their dif-
ferentiation into bone and cartilage phenotypic cells
[80]. They verified that laser-assisted bioprinting was
capable of printing with a high cell density, which is es-
sential for 3D tissue formation, and maintained cell via-
bility during the printing process. Moreover, the MSC
differentiation ability was observed from the expression
of the osteogenic markers OCN and ALP and the chon-
drogenic markers collagen type II and aggrecan.
Applications of cell encapsulation as regenerative
medicine
Cell encapsulation technologies provide a biomimetic
3D environment for MSCs to maintain their viability
and functionality, resulting in their differentiation into
many types of tissue. The spatiotemporal 3D environ-
ment affects MSC fate by matrix composition, substrate
stiffness, porosity, and substrate structure. The different
3D environments influence integrin interaction and
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clustering between the MSCs and matrix which have cell
adhesion and proliferation. These affect the signaling of the
cell, that is transduced to the nucleus to regulate gene ex-
pression and consequently to alter the cell phenotype [81].
Therefore, tissue regeneration requires various environ-
ments depending on a tissue type, because of their distinct
ECM parameters, respectively. In addition, biomechanical
stimuli are not enough to enhance MSC differentiation, so
the combination with biochemical components such as
growth factors including BMP-2, TGF- β1, VEGF, and FGF
is critical [82]. 3D encapsulation technologies can provide
physicochemical effects on MSCs by encapsulating both
MSCs and growth factors. Thus, MSC encapsulation
technologies that can provide diverse shapes, sizes,
and matrix compositions with biochemical cues must
be optimized depending on a targeted tissue. Among
the various types of tissue, cartilage and bone are rep-
resentatives of well-studied hard tissues. Moreover,
the skin is a normal soft tissue that has been exten-
sively studied. Blood vessel regeneration is also an im-
portant consideration because it is an essential
requirement for all tissue regenerations. In this sec-
tion, we will discuss the use of the MSC encapsula-
tion technologies described above for the regeneration
of these four types of tissue.
Cartilage
Injured cartilage is one of the most difficult tissues to
regenerate because it is one of the avascular tissues
with a limited supply of oxygen and nutrients. As a
conventional treatment, autologous chondrocyte cell
therapy has been widely applied, but it has drawbacks,
such as its complexity, loss of cell functionality, and in-
complete healing. Therefore, the method of MSC deliv-
ery to the defective site to induce differentiation toward
chondrocytes is an emerging therapy for cartilage re-
generation. Many research groups have examined vari-
ous types of 3D environment scaffolds for delivering
MSCs and inducing chondrogenesis. Peter et al. used
extrusion bioprinting to encapsulate hBMSCs and hu-
man nasal chondrocytes creating human cartilage in
vivo (Fig. 3A) [83]. Encapsulated hBMSCs enhanced the
proliferation of chondrocytes and the formation of car-
tilage clusters. In addition, using a microfluidic device,
Alireza et al. established a co-delivery system of
TGF-β1 and human dental MSCs (hDMSCs) in
RGD-coupled alginate microspheres (Fig. 3B) [84]. In
their study, the hDMSCs (2 × 106/ml in alginate) differ-
entiated into chondrocytes upon the presentation of
TGF-β1 as an inductive signal. The alginate
microsphere-using microfluidic device was simple and
maintained MSC viability and chondrogenic differenti-
ation properly.
Bone
The implantation of a cell-laden 3D scaffold is important
for the induction of osteogenesis in MSCs and the re-
construction of bone tissue. Leslie et al. encapsulated
rADSCs in alginate and alginate-lyase combination
Fig. 3 Application of MSC encapsulation for cartilage regeneration. A (a) Cell-encapsulated nanofibrillated cellulose bioprinting gel. (b) Chondrocyte
proliferation in 3D-bioprinted scaffold with hNCs and hBMSCs at day 30 (left) and day 60 (right) after subcutaneous implantation. Reproduced with
permission from Reference [83]. Copyright 2017 PLOS. B (a) The periodontal ligament stem cells (PDLSCs), gingival mesenchymal stem cells (GMSCs),
and hBMSC-encapsulated RGD-coupled alginate microbeads with TGF-β1 by microfluidic device. (b) MSC-encapsulated microbeads stained safranin-O
and toluidine blue that indicates proteoglycans, significantly. Reproduced with permission from Reference [84]. Copyright 2013 Elsevier
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hydrogel microbeads (< 200 μm) at a concentration of
25 × 106 cells/ml using an electrostatic droplet generator
(Fig. 4A) [85]. They controlled the degradation rate via
the ratio of alginate-lyase to alginate for maintaining
rADSCs viability in the injured site. The rADSCs re-
leased from the alginate-lyase microbeads were still vi-
able after 12 days, and they released a high level of bone
morphogenetic protein 2, VEGF-A, and FGF2, which are
factors that stimulate bone regeneration. In another study
group, Daniela et al. encapsulated hBMSCs in 3D
agarose-collagen scaffold using inkjet bioprinting [86].
They confirmed that agarose is important to increase bio-
printing contour accuracy, and collagen is crucial to en-
hance hBMSC proliferation resulting in osteogenic
differentiation. As a result, high collagen concentration of
scaffold was effective for bone regeneration. Chan et al.
studied assembled cell spheroids by application of the
microfluidic-based water-in-oil-in-water double-emulsion
method [87]. The aggregated hBMSCs formed spheroids
in the alginate and RGD-modified alginate droplets using
8 × 106 cells/ml. Furthermore, the hBMSC spheroids in
the RGD-modified alginate showed enhanced osteogenic
differentiation after 7 days in culture. The successful bone
regeneration was clarified by alizarin red staining and an
increase in ALP activity (Fig. 4B).
Skin
There has been a lot of research to reconstruct dam-
aged skin, which covers most of the human body.
Generally, burned tissue and chronic wounds have
been successfully treated with scaffold-based tissue
constructs [88]. Kim et al. introduced a skin-derived
ECM bioink to fabricate a 3D thickness skin con-
struct by bioprinting [89]. They made a 3D-printed
skin patch with hADSCs and endothelial progenitor
cells for wound healing. In vivo results demonstrated
that the hADSCs enhanced wound healing, re-epithe-
lialization, and the formation of new blood vessels
that realize skin regeneration using 6 × 106 cells/ml in
media (Fig. 5A). Skardal et al. also used bioprinting
technology to form full-thickness skin tissue on mice
wounds [90]. hBMSCs and human amniotic fluid
MSCs (hAFMSCs) that were suspended separately in
a fibrin-collagen gel were printed over the wound site
of mice. The hBMSC- and hAFMSC (5 × 106 cells/
scaffold)-encapsulated scaffolds accelerated wound
Fig. 4 Effective MSCs delivery for bone regeneration. A (a) Release of ADSCs from alginate microbeads with different concentration of alginate-
lyase by electrostatic droplet extrusion. (b) ADSC-encapsulated alginate-lyase microbeads revealed high expression of BMP-2 and FGF-2 that regulates
bone regeneration. Reproduced with permission from Reference [85]. Copyright 2013 Elsevier. B (a) Printed agarose-collagen 3D columns and rings
using inkjet bioprinting. (b) Alizarin red staining for hBMSC-loaded agarose-collagen hydrogel scaffold. Reproduced with permission from Reference
[86]. Copyright 2016 John Wiley and Sons
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closure and re-epithelialization more significantly than
did a cell-free fibrin-collagen scaffold. They concluded
that growth factors secreted by hAFMSCs had in-
duced angiogenesis and wound closure at the injured
site (Fig. 5B).
Blood vessel
The reconstruction of blood vessels plays a key role in tis-
sue regeneration because they supply oxygen and nutrients
to tissues. As the source for regenerating blood vessels,
MSCs are good candidates considering their unique antith-
rombogenic properties, immune response, and multipo-
tency to differentiate into vascular phenotypes. Trkov et al.
emphasized that unraveling the mechanism of blood vessel
formation would offer therapeutic solutions because there
are many limitations in oxygen and nutrient supply [36].
HUVEC- and hBMSC-encapsulated hydrogels were local-
ized for each channel using microfluidic patterning (106
cells/100 μl in PBS). The authors used a simple and robust
mold to study communication within the cells of relevance
for vascularized tissue engineering (Fig. 6A). Liu et al. in-
vestigated small diameter of vascular grafts through micro-
fiber using microfluidic device. Encapsulated mouse
BMSCs proliferated in the microfibers with VEGF and
fibroblast growth factor (FGF) showed stable vascular
regeneration (Fig. 6B) [65]. Jeon et al. described a number
of factors related to vessel development, and the
non-endothelial cell-specific growth factors, such as the
proteins of the TGF family that are also required for angio-
genesis [91]. They demonstrated that two endothelial
cell-related molecules, angiopoietin and TGF-β1, released
from encapsulated hBMSCs (6 × 106 cells/ml in hydrogel
suspension) using a microfluidic device, played an import-
ant role in angiogenesis.
Conclusion
Tissue regeneration is one of the most prominent and
vital approaches in diverse biomedical applications.
Fig. 5 MSC encapsulation using bioprinting for treatment of skin regeneration. A (a) Printability test of dECM bioink through the production of
heterogeneous structure by modeling. (Bioink A: cell-free S-dECM bioink was stained with rhodamine (red); bioink B: cell-free S-dECM bioink was
stained with trypan blue(blue). (b) The images of wound healing for 21 days. Reproduced with permission from Reference [89]. Copyright 2018
Elsevier. B Schematic diagram illustrating an approach to bioprinting amniotic fluid-derived stem (AFS) cells to increase the healing of
full-thickness skin wounds. Reproduced with permission from Reference [90]. Copyright 2012 John Wiley and Sons
Kim et al. Stem Cell Research & Therapy           (2019) 10:51 Page 10 of 14
MSCs, which are known to have a lot of potential
and play an increasingly leading role in tissue engin-
eering and regenerative medicine, have only recently
been applied as a biomedicine. In this review, we
have investigated various MSC encapsulation tech-
nologies and their applications in tissue regeneration.
For clinical applications, we need to use a variety of
techniques, but among them, we have looked at four
technologies: micromolding, electrostatic droplet ex-
trusion, microfluidics, and bioprinting. The advantages
of MSC encapsulation technologies are improvement
of MSC viability, proliferation, differentiation capacity,
and protection of MSCs from the immune system in
the body. These technologies which are composed
using 3D environment structure can provide safe de-
livery of MSCs into a specific site of defection, which
can provide long-term cell-based therapy for tissue
regeneration. Therefore, mass production of MSCs
and scaled-up matrix are critical challenges that are
to be considered for clinical application of the tissue
regeneration. In other words, cost, time, and labor ef-
ficiency of cell encapsulation and transplantation are
challenges. Additional challenge is to consider the en-
capsulation biomaterial as the immune response to
the implanted MSC-encapsulated matrix. Thus, the
simple and easy technique to encapsulate MSCs and
a combination of biocompatible materials must be
improved for effective tissue regeneration.
Previous tissue engineering methods using MSC en-
capsulation have used each technology of micromolding,
electrostatic droplet extrusion, microfluidics, and bio-
printing individually. However, we need to combine
these technologies to overcome the limitations of each
and thereby increase their advantages. Besides this, al-
though MSCs are considered to be an attractive cell
source owing to their multipotency, it is difficult to ig-
nore their possible differentiation into an abnormal tis-
sue. Through a preliminary study of the differentiation
of MSCs and their effects, diseases caused by unex-
pected differentiation can be prevented and treated.
Therefore, MSC encapsulation technology has the po-
tential to be utilized infinitely in therapeutic medicine by
suppressing the abnormal differentiation and side effects
of MSCs. In conclusion, MSC encapsulation is a very
promising technology for use in tissue engineering and
regenerative medicine applications, depending on the
occasion and purpose.
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